BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T172512
CREATED:20201022T103840Z
LAST-MODIFIED:20201022T104916Z
UID:27595-1615248000-1615507199@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders 2021
DESCRIPTION:2020 has been an exciting year for Gene Therapies targeting Blood Disorders. Despite FDA’s recent rejection of BioMarin’s hemophilia gene therapy program\, the clinical landscape is progressing quickly with Pfizer and Sangamo kicking off their phase 3 and bluebird bio receiving European approval for their beta-thalassemia candidate. With pipelines advancing and emerging companies joining the blood disorders field\, it is essential for gene therapy developers to communicate and share lessons learned to accelerate their programs to market. \n \nThe 2nd Gene Therapy for Blood Disorders meeting is taking place in March 2021\, focusing on the clinical and commercial challenges of developing gene therapies targeting hemophilia\, sickle cell disease and beta thalassemia. Evaluate the best strategies for a commercial launch in blood disease and optimize your trial design to ultimately transform your clinical candidates into a commercial reality. \nTo know more about Gene Therapy for Blood Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR